Convatec Maintains New Growth Trajectory Thanks to New Products

Since its initial public offering, Convatec has followed a familiar playbook to press its advantage in advanced wound care and to enhance its ostomy business. By and large, we like Convatec’s businesses that focus on chronic care, which translates into an ongoing stream of revenue. However, the company stumbled badly out of the gate and lagged significantly behind its key competitor, Coloplast. Fortunately, management has been making notable progress to remedy this situation..